It's Trump or Clinton for President. But what are the implications for pharma?

Batch or continuous processing? For mAbs, a hybrid approach could be best.

David Banks offers a warning on using inappropriate lyophilization placebos.

Costs of failing to communicate can cost you collaboration and investment.

Have Mylan been their own worst enemy with an imprudent pricing decision?

Emma Walmsley is chosen as GlaxoSmithKline's new CEO.

Richard Bergstrom has resigned from EFPIA - who will replace him?

Critics say a report from the UN on access to medicines ignores the real word industry

Our infographic looks at how the CPhI trade show has grown over the years.

Researchers say cancer should involve more frequent treatment at lower doses.